

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF

02 AUG 14 PM

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>GlaxoSmithKline</b>			
2. Address <input type="checkbox"/> Check if different than previously reported <b>1500 K Street, NW Suite 650</b>			
3. Principal Place of Business (if different from line 2) City: <b>Washington, DC</b> State/Zip (or Country) <b>20005</b>			
4. Contact Name <b>Janie A. Kinney</b>	Telephone <b>202-715-1000</b>	E-mail (optional)	5. Senate ID# <b>16293-12</b>
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID# <b>31461000</b>

**TYPE OF REPORT** 8. Year 2002 Midyear (January 1-June 30)  Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_ 11. No Lobbying Activity

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organization</b></p> <p>EXPENSES relating to lobbying activities for this report were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>1,600,000.00</u> Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts used LDA defini</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 60 of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 16 Internal Revenue Code</p>
--	--

Signature

*Janie Ann Kinney*

Date

August 14, 2002

Printed Name and Title

Janie A. Kinney, Vice President, Federal Government Relations & Public Policy



Registrant Name GlaxoSmithKline Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each coc** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

- S. 754 The Drug Competition Act of 2001
- S. 812 Greater Access to Affordable Pharmaceuticals Act
- H.R. 1862 Greater Access to Affordable Pharmaceuticals Act
- H.R. 741 Madrid Protocol Implementation

17. House(s) of congress and Federal agencies contacted  Check if None

U.S. House Of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Mary Frances Daly	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature *Janie A. Kinney* Date August 14, 2002

Printed Name and Title Janie A. Kinney, Vice President, Federal Government Relations & Public Policy



Registrant Name GlaxoSmithKline Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S. 358 Medicare Prescription Drug & Modernization Act of 2001  
 H.R. 1400 Prescription Drug Fairness for Seniors Act of 2001  
 H.R. 1229 Medicare, Medicaid and MCH Smoking Cessation Promotion Act  
 S. 854 Medicare, Medicaid and MCH Smoking Cessation Promotion Act

17. House(s) of congress and Federal agencies contacted  Check if None

U. S. House  
 U. S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Mary Frances Daly	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature *Janie Ann Kinney* Date August 14, 2002

Printed Name and Title Janie A. Kinney, Vice President, Federal Government Relations & Public Policy



Registrant Name GlaxoSmithKline Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

S. 1764 Biological and Chemical Weapons Research Act  
 H.R. 3448 Public Health Security and Bioterrorism Response Act of 2001  
 H.R. 2116 Supplemental Appropriations Act  
 H.R. 1504 Vaccines for the New Millennium Act  
 S. 895 Vaccines for the New Millennium Act  
 H.R. 580 Comprehensive Insurance Coverage of Childhood Immunization  
 H.R. 3338 DoD Appropriations Act of 2002  
 H.R. 3061 Department of Labor, Health, & Human Services & Education, Related Agencies Appropriations Act  
 S. 1536 Department of Labor, Health, & Human Services & Education, Related Agencies Appropriations Act

17. House(s) of congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
 U.S. Senate  
 Office of Management & Budget  
 HHS

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Mary Frances Daly	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature

*Janie Ann Kinney*

Date

August 14, 2002





Registrant Name GlaxoSmithKline Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each coc** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

- S. 838 The Best Pharmaceuticals for Children Act
- S. 2330 Agriculture Appropriations Act of 2002
- S. 1731 Puppy Protection Act
- H. Con. Res. 197 Chronic Obstructive Pulmonary Disease Awareness Month
- H.R. 2887 Best Pharmaceuticals for Children Act

17. House(s) of congress and Federal agencies contacted  Check if None

- U. S. House of Representatives
- U. S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Mary Frances Daly	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature *Janie Ann Kinney* Date August 14, 2002



Registrant Name GlaxoSmithKline Client Name Self

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

Mary Frances Daly

**ISSUE UPDATE**

24. General lobbying issues previously reported that **no longer** pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	(in thousands of dollars)
NONE				

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, client or affiliated organization

Signature

*Janie Ann Kinney*

Date

August 14, 2002

Printed Name and Title

Janie A. Kinney, Vice President, Federal Government Relations & Public Policy

